Research Funding

  • February 1, 1997 - March 31, 2006 - Tumor Necrosis Factor Action in Cells, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA067891
  • September 1, 1997 - June 30, 2004 - VASCULAR ENDOTHELIAL CELL GROWTH FACTOR IN PATHOLOGY, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA073023
  • September 6, 1996 - January 31, 1997 - TUMOR NECROSIS FACTOR ACTION IN CELLS, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R55CA067891
  • March 1, 1988 - February 28, 1994 - TUMOR NECROSIS FACTOR RECEPTOR--STRUCTURE AND FUNCTION, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA044747

Education

Queens College, New York, NY, B.A., 1966, Chemistry
Rensselaer Polytechnic Institute, New York, NY, Ph.D., 1972, Chemistry
Cornell University, Ithaca, NY, post-doc, 1972-1973, Biochemistry

Honors & Awards

  • 7/82 to 6/87
    NIH Career Development Award
  • 1/82 to 6/82
    American Cancer Society Faculty Research Award
  • 1984
    Louise & Alston Boyer Young Investigator Award for Laboratory Research
  • 1978-79
    American Diabetes Association Research and Development Award
  • 1962-1966
    NY State Regents Scholarship
  • 1962-1966
    NY State Scholar Incentive Award

Selected Publications

  1. Ricardo J. Antonia, Kan Toriguchi, Eveliina Karelehto, Dania Annuar, Luika Timmerman, Noura Tbeileh, Aras N. Mattis, Carlos U. Corvera, Kenzo Hirose, Eric K. Nakakura, David B. Donner, Robert S. Warren Patient-derived organoids for personalized drug screening in intrahepatic cholangiocarcinoma.  View on PubMed
  2. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.  View on PubMed
  3. Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.  View on PubMed
  4. Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.  View on PubMed
  5. K. Toriguchi, M. Lin, E. Nakakura, C. Corvera, B. Hann, D. Donner, R. Warren An approach to patient-specific treatment of intrahepatic cholangiocarcinoma (ICC): drug screens with patient-derived spheroids identify mTOR as a viable and druggable target.  View on PubMed
  6. Tartaglione G, Stoeckli SJ, de Bree R, Schilling C, Flach GB, Bakholdt V, Sorensen JA, Bilde A, von Buchwald C, Lawson G, Dequanter D, Villarreal PM, Forcelledo MF, Amezaga JA, Moreira A, Poli T, Grandi C, Vigili MG, O'Doherty M, Donner D, Bloemena E, Rahimi S, Gurney B, Haerle SK, Broglie MA, Huber GF, Krogdah AL, Sebbesen LR, Odell E, Junquera Gutierrez LM, Barbier L, Santamaria-Zuazua J, Jacome M, Nollevaux MC, Bragantini E, Lothaire P, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, Colletti PM, Rubello D, McGurk M Sentinel Node in Oral Cancer: The Nuclear Medicine Aspects. A Survey from the Sentinel European Node Trial.  View on PubMed
  7. Maines F, Caffo O, Donner D, Sperduti I, Bria E, Veccia A, Chierichetti F, Tortora G, Galligioni E Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.  View on PubMed
  8. Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA, Bakholdt V, Krogdahl A, von Buchwald C, Bilde A, Sebbesen LR, Odell E, Gurney B, O'Doherty M, de Bree R, Bloemena E, Flach GB, Villarreal PM, Fresno Forcelledo MF, Junquera Gutiérrez LM, Amézaga JA, Barbier L, Santamaría-Zuazua J, Moreira A, Jacome M, Vigili MG, Rahimi S, Tartaglione G, Lawson G, Nollevaux MC, Grandi C, Donner D, Bragantini E, Dequanter D, Lothaire P, Poli T, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, McGurk M Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer.  View on PubMed
  9. Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.  View on PubMed
  10. Farkas C, Martins CP, Escobar D, Hepp MI, Castro AF, Evan G, Gutiérrez JL, Warren R, Donner DB, Pincheira R Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress.  View on PubMed
  11. Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.  View on PubMed
  12. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.  View on PubMed
  13. Schiavi F, Demattè S, Cecchini ME, Taschin E, Bobisse S, Del Piano A, Donner D, Barbareschi M, Manera V, Zovato S, Erlic Z, Savvoukidis T, Barollo S, Grego F, Trabalzini F, Amistà P, Grandi C, Branz F, Marroni F, Neumann HP, Opocher G The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression.  View on PubMed
  14. Gregory S. Ducker, Chloe Evelyn Atreya, Jeffrey Simko, Eric K. Nakakura, Emily K. Bergsland, David B. Donner, Kevan M. Shokat, Robert S. Warren Effect of PIK3CA and KRAS mutations on sensitivity to ATP-competitive mTOR inhibitors in a primary xenograft model of colorectal carcinoma.  View on PubMed
  15. Lin CI, Barletta JA, Nehs MA, Morris ZS, Donner DB, Whang EE, Jeong JW, Kimura S, Moore FD, Ruan DT Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-?B activity.  View on PubMed
  16. Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J, Luo X, Clarke D, Lamba J, Schuetz E, Donner DB, Puli N, Falck JR, Capdevila J, Gupta K, Blair IA, Potter DA CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET).  View on PubMed
  17. Y. Wang, D. Donner, A. Venook, E. Bergsland, R. Warren, E. Nakakura A Primary Xenograft Model of Pancreatic Neuroendocrine Carcinoma Maintains a Neuroendocrine Tumor Gene Expression Signature.  View on PubMed
  18. Chi-Iou Lin, Jinyan Du, Wen Shen, Edward E. Whang, David B. Donner, Nick Griff, Frank He, Francis D. Moore, Orlo H. Clark, Daniel T. Ruan Mitogen-Inducible Gene-6 Is a Multifunctional Adaptor Protein with Tumor Suppressor-Like Activity in Papillary Thyroid Cancer.  View on PubMed
  19. Chi-Iou Lin, Jinyan Du, Wen Shen, Edward E. Whang, David B. Donner, Nick Griff, Frank He, Francis D. Moore, Orlo H. Clark, Daniel T. Ruan Mitogen-Inducible Gene-6 Is a Multifunctional Adaptor Protein with Tumor Suppressor-Like Activity in Papillary Thyroid Cancer.  View on PubMed
  20. Lin CI, Du J, Shen WT, Whang EE, Donner DB, Griff N, He F, Moore FD, Clark OH, Ruan DT Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer.  View on PubMed

Go to UCSF Profiles, powered by CTSI